DEA’s 2020 Rule Opened the Door to Better Cannabis Research

For decades, federally authorized cannabis research in the United States depended largely on one source: cannabis cultivated at the University of Mississippi under contract with the National Institute on Drug Abuse. That arrangement provided a controlled supply for studies, but researchers and independent reviews criticized the material for failing to reflect the potency, genetics, formulations and delivery methods found in state-licensed markets.

The Drug Enforcement Administration’s December 2020 final rule on cannabis cultivation for research, which took effect on January 19, 2021, addressed one of the system’s most persistent bottlenecks. The rule established a framework for registering additional manufacturers to grow and supply cannabis for federally authorized research and other permitted purposes.

Why the single-source system was a problem

The University of Mississippi’s cannabis program began in 1968 and remains an important part of the federal research infrastructure. The university says it produces standardized plant material, extracts and other products for the NIDA Drug Supply Program. But a standardized research supply is not necessarily representative of the products used by patients and consumers.

Researchers have reported that some government-grown cannabis was relatively low in THC and differed substantially from products available through state-regulated dispensaries. A 2021 genetic analysis found that federally supplied samples were distinct from the retail drug-type cannabis examined by the researchers. The study did not establish that the government supply was literally hemp, but it did underscore the difficulty of generalizing results from federally supplied material to the products people use outside the laboratory.

Clinical investigators have also described practical problems involving potency, storage and product form. A trial involving cannabis for military veterans, for example, drew attention to the gap between the material researchers were required to use and the cannabis available to potential patients. Those differences matter because the effects of cannabis can vary according to cannabinoid ratios, dosage, cultivation practices and whether the product is inhaled, swallowed or delivered in another form.

What the DEA rule changed

The rule did not legalize cannabis or remove marijuana from Schedule I of the federal Controlled Substances Act. Instead, it created clearer procedures for entities seeking DEA registration as bulk manufacturers of cannabis for research. Applicants must demonstrate appropriate state authorization, show that their customers are properly licensed and maintain safeguards against diversion.

Under the framework, approved producers can cultivate, process, store and distribute research cannabis under DEA oversight. That creates the possibility of a broader range of flower, extracts, cannabinoid preparations and other dosage forms for preclinical studies, clinical trials and pharmaceutical development.

The DEA described the change as a way to expand opportunities for medical and scientific research while complying with federal law and U.S. treaty obligations. In 2021, the agency began moving several applicants through memorandums of agreement and said additional registered producers could eventually support more than 575 DEA-licensed researchers. The agency now maintains a list of DEA-approved bulk cannabis manufacturers.

George Hodgin, chief executive of Biopharmaceutical Research Co., was among the industry representatives who viewed the policy as a major opportunity. Companies such as BRC and Groff North America argued that access to federally compliant, higher-quality material could support the development of standardized medicines, active pharmaceutical ingredients and other research products.

More than a question of THC potency

Researchers have emphasized that improving cannabis research requires more than simply increasing THC levels. Igor Grant of the University of California San Diego’s Center for Medicinal Cannabis Research has noted that scientists need access to different cannabinoid combinations, consistent batches and multiple delivery methods.

That distinction is important. A cannabis preparation containing 13% THC is not automatically equivalent to a dispensary product with the same labeled potency. Other cannabinoids, terpenes, contaminants, extraction methods, dose size and route of administration can all affect the results of a study. Reliable research therefore depends on products that are chemically characterized and consistently manufactured, not merely on products with higher THC concentrations.

Cannabis researcher Ethan Russo welcomed the possibility of domestically produced, standardized cannabis-derived medicines but remained cautious. Regulatory promises have been made before, and the existence of a new approval pathway does not by itself guarantee that researchers will quickly receive the materials they need.

Steven Groff, founder of Groff North America, similarly argued that data-driven research is necessary to determine which potential medical applications are supported by evidence. The new framework broadened the types of cannabis preparations that registered companies could seek to manufacture, subject to federal approvals and applicable controls.

A research reform, not a legalization measure

The rule’s significance should not be overstated. It did not change marijuana’s federal scheduling or establish that cannabis has an accepted medical use under the Controlled Substances Act. Nor did it authorize unrestricted interstate commerce in cannabis. Cultivators and researchers still operate under DEA registration requirements, production quotas, security rules and other federal restrictions.

Its importance lies in addressing a more specific problem: whether U.S. research can be conducted with cannabis that is sufficiently diverse and representative to answer the questions patients, physicians and regulators actually face.

That concern has continued to shape federal policy. In December 2022, Congress enacted the Medical Marijuana and Cannabidiol Research Expansion Act, which created additional requirements for processing research applications, maintaining an adequate supply and reducing certain administrative barriers. The law built on, rather than replaced, the DEA’s work to diversify the supply of research cannabis.

Researchers may ultimately need access not only to products manufactured specifically for experiments but also to representative samples of products sold in state-regulated markets. Testing those products could improve studies of cannabis-impaired driving, adverse effects, product safety and real-world medical use. At the same time, such research would require careful safeguards to verify potency and screen for harmful contaminants.

The 2020 DEA rule was therefore a meaningful reform of the research infrastructure surrounding cannabis. It did not settle the broader debate over legalization or medical value, but it helped move U.S. cannabis research away from a single-source model and toward a system capable of producing more varied, consistent and clinically relevant evidence.